Commercial Law
Jan. 12, 2017
Nearly 10-year-old shareholder action against Amgen dismissed
The case was stayed until investor class action claims settled for $95 million last October.
Daily Journal Staff Writer
A federal judge dismissed a nearly decade-old shareholder derivative action against biotech company Amgen Inc. on Tuesday.
The case was stayed for almost 10 years until investor class action claims settled for $95 million last October. Amgen shareholder Judy Durgin sought similar relief from Amgen and 17 executives, alleging insider trading and breach of fiduciary du...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In